A method for evaluating a compound to determine the relative or absolute therapeutic capability of a compound to pharmacologically inhibit ischemia induced activation of iPLA<SUB>2</SUB>beta in an intact myocardium which comprises treating intact myocardium with a compound, inducing ischemia in the myocardium tissue and determining if there has been a change in expression of iPLA<SUB>2</SUB>beta, its activity or in the iPLA<SUB>2</SUB>beta regulating network and determining if there has been a change then that the compound is an anti-arrhythmia or myocardial salvage drug.
Calcium-independent phospholipase A2 induces ischemic ventricular arrhythmias and decreases infarction size